New drug combo aims to slow cervical cancer growth
NCT ID NCT06266338
First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This study is testing whether two drugs, pembrolizumab (Keytruda) and lenvatinib (Lenvima), can slow tumor growth in people with cervical cancer that has spread or come back. About 30 participants will receive the combination. The main goal is to see how many people's tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and lenvatinib (Lenvima)
What this could lead to
If successful, this drug combination could offer a new treatment option to slow tumor growth in people with advanced cervical cancer that has returned or spread.
What could go wrong
This is a small, early-phase (phase 2) study with only 30 participants, so results may not apply to everyone. The combination may cause side effects and might not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.